Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Bioactive Molecules
Natural Products
ADCs
Antibodies
- Primary Antibodies
- Secondary Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 96829-58-2] Orlistat

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-B0218
Brand:	MCE
CAS:	96829-58-2

Overview

MDL	MFCD05662360
Molecular Weight	495.73
Molecular Formula	C29H53NO5
SMILES	O=C1[C@@H](CCCCCC)[C@H](C[C@@H](OC([C@@H](N([H])C([H])=O)CC(C)C)=O)CCCCCCCCCCC)O1

For research use only. We do not sell to patients.

6 Publications Citing Use of MCE

[1]Acta Pharm Sin B. 15 January 2022.
[2]J Exp Clin Cancer Res. 2023 Jan 6;42(1):6.
[3]Anal Chem. 2020 Mar 17;92(6):4419-4426.
[4]Int J Biol Sci. 2021 Oct 11;17(15):4207-4222.
[5]Nutrients. 2018 Mar 15;10(3). pii: E353.
[6]Int Immunopharmacol. 2021 Oct 13;101(Pt B):108225.

Summary

Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases . Orlistat is also an inhibitor of fatty acid synthase ( FASN ), is used orally for long-term research of obesity ^[1] . Anti-atherosclerotic effect ^[2] .

In Vitro

Orlistat (40 μM; 2 days) does not affect MGMT levels in a human melanoma cell line, but downregulates the repair protein by 30-70% in human peripheral blood mononuclear cells, in two leukemia and two colon cancer cell lines. Orlistat does not alter noticeably MGMT mRNA expression ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis ^[1]

Cell Line:	The human melanoma cell line M10, Peripheral blood mononuclear cells , The human Jurkat CD4 ⁺ T cell leukemia cell line, the human promyelocytic leukemia cell line HL-60, the epithelial colon cancer HCT116 cells,non adherent mononuclear cells (NAMNC) ^[1]
Concentration:	2.5, 5, 10, 20, 40 μM for Jurkat cells; 20 and 40 μM for HCT116 cells; 40 μM for normal NAMNC, M10 melanoma, HL-60 promyelocytic leukemia, and HT-29 colon cancer cells
Incubation Time:	2 days for Jurkat cells; 2 or 4 days for HCT116 cells; 2 days for NAMNC, M10 melanoma, HL-60 promyelocytic leukemia, HT-29 colon cancer
Result:	Reduced by >50% the MGMT level at the concentration of 40 μM for Jurkat cells, whereas little or no effect was found when lower concentrations were used. Downregulation of MGMT expression is produced at 40 μM for HCT116 cells. Provoked an ~50% reduction of MGMT level at 40 μM in normal NAMNC, and HL-60 promyelocytic leukemia, HT-29 colon cancer cells except for melanoma M10 cells that showed no downregulation of the protein.

In Vivo

Orlistat (10 mg/kg/day) significantly improves lipid profile, increases antioxidant enzymes and expression of anti-inflammatory markers, and decreases the expression of the pro-inflammatory marker compared to the obese (OB) group ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Eighteen male rats of Sprague–Dawley strain aged between 8–10 weeks weighing 200-250 g ^[2]
Dosage:	10 mg/kg/day
Administration:	Orally; six weeks
Result:	Treatment persistently restored the increased body weight, which was significantly observed at the ninth week until the end of the experimental period.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01003483	Yazd Research & Clinical Center for Infertility\|Yazd Medical University	Obesity	December 1, 2008	Phase 2
NCT01184560	Gachon University Gil Medical Center	Obesity	February 2010	Not Applicable
NCT00156897	Alizyme	Non-Insulin-Dependent Diabetes Mellitus\|Obesity	December 2004	Phase 2
NCT03383068	RenJi Hospital	PCOS\|Impaired Glucose Tolerance	January 1, 2018	Phase 4
NCT00461799	University Medical Center Groningen\|Erasmus Medical Center\|De Najjar Stichting	Crigler-Najjar Syndrome	September 2003	Not Applicable
NCT02432209	Yale University\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\|Penn State University\|Augusta University\|University of California, San Francisco\|University of North Carolina\|University of Oklahoma\|University of Pennsylvania	Infertility, Female	August 2015	Phase 3
NCT01351753	University of Iowa	Obesity\|Metabolic Syndrome X	March 2011	Phase 2
NCT01755676	EMS	Obesity	September 2016	Phase 3
NCT01597531	East Carolina University	Type 2 Diabetes\|Gastric Banding	June 2012	Phase 4
NCT02069197	Mid-Atlantic Epilepsy and Sleep Center, LLC	Obesity\|Diabetes\|Obstructive Sleep Apnea	January 2014	Phase 2
NCT05579249	Novo Nordisk A+S	Obesity	January 20, 2023	Phase 4
NCT01035333	Albany College of Pharmacy and Health Sciences\|Albany Medical College	Obesity	November 2009	Phase 4
NCT00752726	GlaxoSmithKline	Obesity\|Overweight	September 2008	Phase 4
NCT01675154	University of Texas Southwestern Medical Center	Type 1 Hyperlipoproteinemia	November 2015	Phase 2
NCT00212199	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|Hoffmann-La Roche	1. Obesity	January 2002	Phase 4
NCT00152360	University of British Columbia	Obesity\|Heart Diseases	June 2005	Phase 4
NCT00991926	Federico II University	Obesity	December 2006
NCT00001723	Jack Yanovski\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\|Roche Pharma AG\|National Institutes of Health Clinical Center (CC)	Diabetes Mellitus\|Hypertension\|Metabolic Disease\|Obesity\|Sleep Apnea Syndrome	May 1998	Phase 2
NCT01550926	GlaxoSmithKline	Overweight	February 2009	Phase 1
NCT01475019	Aristotle University Of Thessaloniki	Obesity\|Polycystic Ovaries Syndrome	January 2004	Phase 4
NCT01387243	GlaxoSmithKline	Overweight	January 2010
NCT01797757	Nestlé	Obesity	January 2012	Not Applicable
NCT05076474	Shandong New Time Pharmaceutical Co., LTD	Bioequivalence	October 1, 2020	Not Applicable
NCT02706067	Hoffmann-La Roche	Obesity	July 2002	Phase 4
NCT03675191	Gangnam Severance Hospital	Obesity\|Overweight	October 16, 2018	Not Applicable
NCT05496075	Shanghai 10th People´s Hospital	Uric Acid	August 26, 2022	Phase 3
NCT01719419	Pennington Biomedical Research Center	Overweight	March 2012	Not Applicable
NCT03582722	Emory University\|Healthway Compounding Pharmacy in central Michigan\|Michigan Public Health Departments\|National Institute of Environmental Health Sciences (NIEHS)	Polybrominated Biphenyl Poisoning	September 14, 2018	Phase 4
NCT00292799	Sheffield Teaching Hospitals NHS Foundation Trust\|Hoffmann-La Roche	Anovulation\|Obesity	February 2006	Not Applicable
NCT01170806	University of Campinas, Brazil\|Germed Pharma	Obesity	October 2009	Not Applicable
NCT03884127	Fifth Affiliated Hospital of Xinjiang Medical University\|West China Hospital	Hyperlipidemia	April 1, 2019
NCT04531176	The Cleveland Clinic	Type 2 Diabetes\|Obesity	September 1, 2020	Phase 4
NCT00160407	St. Louis University\|Hoffmann-La Roche	Fatty Liver\|Hepatitis	October 2003	Phase 4
NCT00422058	Novo Nordisk A+S	Metabolism and Nutrition Disorder\|Obesity	January 10, 2007	Phase 2
NCT02767531	University of Texas Southwestern Medical Center	Hyperlipoproteinemia Type I\|Hypertriglyceridemia	December 2015	Phase 2
NCT01047657	University of Sao Paulo General Hospital\|Fundação de Amparo à Pesquisa do Estado de São Paulo	Asthma\|Obesity\|Weight Loss	November 2009	Phase 3
NCT00108524	US Department of Veterans Affairs\|VA Office of Research and Development	Diabetes Mellitus\|Obesity	July 2004	Not Applicable
NCT01414465	University of Campinas, Brazil\|Germed Pharma	Overweight	October 2009	Not Applicable
NCT00940628	Hoffmann-La Roche	Obesity	April 2008	Phase 3
NCT01332448	GlaxoSmithKline	Obesity	February 2010
NCT02529631	Certmedica International GmbH	Overweight\|Obesity	November 2009	Not Applicable
NCT01126970	Shionogi\|Shionogi Inc.	Obesity	April 2010	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 201.72 mM ; Need ultrasonic)

H ₂ O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.0172 mL	10.0861 mL	20.1723 mL
5 mM	0.4034 mL	2.0172 mL	4.0345 mL
10 mM	0.2017 mL	1.0086 mL	2.0172 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (5.04 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: 2.5 mg/mL (5.04 mM); Suspended solution; Need ultrasonic
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.04 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Giorgia Cioccoloni, et al. Influence of fatty acid synthase inhibitor orlistat on the DNA repair enzyme O6-methylguanine-DNA methyltransferase in human normal or malignant cells in vitro. Int J Oncol. 2015 Aug;47(2):764-72.
[2] Zaidatul Akmal Othman, et al. Anti-Atherogenic Effects of Orlistat on Obesity-Induced Vascular Oxidative Stress Rat Model. Antioxidants (Basel). 2021 Feb 6;10(2):251.

Synonyms

L-Leucine, N-formyl-, (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester

L-Leucine, N-formyl-, 1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester, [2S-[2α(R*),3β]]-

Tetrahydrolipstatin

(-)-Tetrahydrolipstatin

Ro 18-0647/002

Orlistat

Xenical

Listata

Alli

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart